Post‐transplant lymphoproliferative disorder of the adrenal gland after allogeneic hematopoietic stem cell transplantation: report of two cases and literature review. Issue 6 (13th November 2015)

• Record Type: Journal Article
• Authors: Kasahara, H.; Mori, T.; Kato, J.; Koda, Y.; Kohashi, S.; Kikuchi, T.; Sakurai, M.; Yamane, Y.; Mikami, S.; Kameyama, K.; Takahashi, Y.; Okamoto, S.
• Is Part Of: Transplant infectious disease. Volume 17:Issue 6(2016)
• Page Start: 909
• Page End: 914
• Publication Date: 2015-11-13
• Subjects: post‐transplant lymphoproliferative disorder -- adrenal gland -- allogeneic hematopoietic stem cell transplantation -- Epstein–Barr virus -- rituximab; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12461
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: Post‐transplant lymphoproliferative disorder (PTLD) is one of the life‐threatening complications after hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT), and it is associated almost exclusively with Epstein–Barr virus (EBV). We herein report 2 cases of EBV‐associated PTLD after allogeneic HSCT localized in the adrenal gland. Both patients developed adrenal tumor within 3 months after HSCT and were successfully treated with rituximab or tapering immunosuppressive agents. Both remained alive without recurrence. A literature review revealed 12 reported cases of PTLD involving the adrenal gland, but the adrenal gland was involved as one of the lesions of advanced‐stage PTLD after SOT. To the best of our knowledge, this is the first report to show cases of isolated EBV‐associated adrenal PTLD after HSCT. PTLD should be recognized as one of the causes of isolated adrenal tumor after HSCT.